Too frequently, they use the term loosely to invoke the concept of innovation in support of whatever it is they wish to do. Many researchers, writers, and consultants use âdisruptive innovationâ to describe any situation in which an industry is shaken up and previously successful incumbents stumble.
Alendronic acid (INN) or alendronate sodium (USAN) â sold as Fosamax by Merck â is a bisphosphonate drug used for osteoporosis and several other bone diseases.It is marketed alone as well as in combination with vitamin D (2,800 IU and 5,600 IU, under the name Fosamax+D).Merck's U.S. patent on alendronate expired in 2008 and the drug is now available as a generic.lendronic acid (INN) or alendronate sodium (USAN) â sold as Fosamax by Merck â is a bisphosphonate drug used for osteoporosis and several other bone diseases.
The drug substance vilanterol trifenatate is the same as that included in Breo Ellipta (New Drug Submission Control number 157301, authorized July 3, 2013). For more information, see the Breo Ellipta Summary Basis of Decision.The information filed for Anoro Ellipta is aligned to that approved by Health Canada for Breo Ellipta (vilanterol trifenatate/fluticasone furoate) manufactured by the same sponsor.he following table describes post-authorization activity for Anoro Ellipta, a product which contains the medicinal ingredients umeclidinium (as umeclidinium bromide) and vilanterol (as vilanterol trifenatate).